Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Biocon Chief Extols Moderna’s Success To Spur ‘Risk-Averse’ VCs in India

Executive Summary

Biocon chairperson Kiran Mazumdar-Shaw says that venture capital firms have, with their risk-averse approach, "failed" the biotech sector in India. The executive draws attention to how "bold" venture funds that backed mRNA technology a decade ago were reaping gains today.

You may also be interested in...



Laronde Aims To Advance Its eRNA Therapies In Eight Weeks, And Has $440m To Help

The Flagship Pioneering-founded start-up will build a “Gigabase Factory” to go from idea to in vivo proof of concept within eight weeks by rapidly manufacturing and running preclinical tests for multiple constructs at once. 

B-Ingelheim India Chief On Strategy, Jardiance Challenge, Gender Balance In Pharma

Boehringer Ingelheim’s Country Managing Director for India Vani Manja outlines how she expects to shape the German group’s growth trajectory in the country, while also dealing with the unexpected pre-expiry challenge to the Jardiance patent. The executive also discusses her personal career journey, learnings from her prior role in the US and gives advice to women executives seeking to move up to the higher echelons of the corporate world.

Biocon Buoyant On ‘Unique Positioning’ Of Partnered COVID-19 Antibody

Biocon management signals the potential of its partnered entry with Serum Institute and Adagio Therapeutics into the communicable diseases segment. Continuing large supply opportunities for COVID-19 vaccines and prospects for boosters, alongside the promising profile of the neutralizing antibody being developed by its US-based partner, also bode well.

Topics

Related Companies

UsernamePublicRestriction

Register

SC145093

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel